[go: up one dir, main page]

MX2014013090A - Derivados de pirrolotriazinona. - Google Patents

Derivados de pirrolotriazinona.

Info

Publication number
MX2014013090A
MX2014013090A MX2014013090A MX2014013090A MX2014013090A MX 2014013090 A MX2014013090 A MX 2014013090A MX 2014013090 A MX2014013090 A MX 2014013090A MX 2014013090 A MX2014013090 A MX 2014013090A MX 2014013090 A MX2014013090 A MX 2014013090A
Authority
MX
Mexico
Prior art keywords
pyrrolotriazinone derivatives
diseases
pyrrolotriazinone
derivatives
imflamination
Prior art date
Application number
MX2014013090A
Other languages
English (en)
Other versions
MX357502B (es
Inventor
Dieter Dorsch
Hans-Peter Buchstaller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2014013090A publication Critical patent/MX2014013090A/es
Publication of MX357502B publication Critical patent/MX357502B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los compuestos de la fórmula I (ver Fórmula) en donde X, R1 e Y tienen los significados indicados en la reivindicación 1, son inhibidores de Tankirasa y se pueden emplear, inter alia, para el tratamiento de enfermedades tales como cáncer, enfermedades cardiovasculares, lesión del sistema nervioso central y diferentes formas de inflamación.
MX2014013090A 2012-05-04 2013-04-06 Derivados de pirrolotriazinona. MX357502B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12003445 2012-05-04
PCT/EP2013/001026 WO2013164061A1 (en) 2012-05-04 2013-04-06 Pyrrolotriazinone derivatives

Publications (2)

Publication Number Publication Date
MX2014013090A true MX2014013090A (es) 2014-12-08
MX357502B MX357502B (es) 2018-07-12

Family

ID=48050660

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013090A MX357502B (es) 2012-05-04 2013-04-06 Derivados de pirrolotriazinona.

Country Status (21)

Country Link
US (1) US9174995B2 (es)
EP (1) EP2844659B1 (es)
JP (1) JP6097820B2 (es)
KR (1) KR20150006873A (es)
CN (1) CN104271580B (es)
AR (1) AR090896A1 (es)
AU (1) AU2013257018B2 (es)
CA (1) CA2872334C (es)
EA (1) EA027628B1 (es)
ES (1) ES2587939T3 (es)
HR (1) HRP20161033T1 (es)
HU (1) HUE028325T2 (es)
IL (1) IL235414A (es)
MX (1) MX357502B (es)
PL (1) PL2844659T3 (es)
PT (1) PT2844659T (es)
RS (1) RS55062B1 (es)
SG (1) SG11201406997WA (es)
SI (1) SI2844659T1 (es)
WO (1) WO2013164061A1 (es)
ZA (1) ZA201408876B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2822656B1 (en) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2014320149A1 (en) 2013-09-11 2016-04-07 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
AU2014372896B2 (en) * 2013-12-23 2018-08-16 Merck Patent Gmbh Imidazopyrazinone derivatives
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
PT3130592T (pt) * 2014-04-10 2019-11-21 Hubei Bio Pharmaceutical Industrial Tech Institute Inc Análogos do composto 4h-pirazolo[1,5-]benzimidazole como inibidores de parp
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
KR101775356B1 (ko) 2015-07-06 2017-09-06 재단법인 아산사회복지재단 Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법
JP6896715B2 (ja) * 2015-09-30 2021-06-30 マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ヴィッセンシャフテン エーファウ −ジェネラルフェルヴァルトゥング セピアプテリン還元酵素としてのヘテロアリール誘導体
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
CN108290896B (zh) * 2015-11-16 2021-09-28 托帕杜制药公司 2-苯基-3,4-二氢吡咯并[2,1-f][1,2,4]三嗪酮衍生物及其用途
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN109180702B (zh) * 2018-10-29 2021-11-30 四川大学 一种噻吩并嘧啶酮化合物及其用途
CN111961058B (zh) * 2020-08-03 2022-12-16 天津全和诚科技有限责任公司 4-氨基-吡咯并三嗪衍生物及其制备方法和用途
EP4504341A1 (en) 2022-04-08 2025-02-12 Shy Therapeutics LLC Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
WO2002004434A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
JP2006521398A (ja) 2003-03-28 2006-09-21 サイオス・インコーポレーテツド ＴＧＦβの二−環式ピリミジン阻害剤
AU2005288858B2 (en) * 2004-09-30 2011-04-21 Janssen R&D Ireland HCV inhibiting bi-cyclic pyrimidines
WO2008092861A1 (en) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
WO2008107478A1 (en) * 2007-03-08 2008-09-12 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors

Also Published As

Publication number Publication date
JP6097820B2 (ja) 2017-03-15
HK1205740A1 (en) 2015-12-24
AU2013257018A1 (en) 2014-12-18
JP2015515961A (ja) 2015-06-04
MX357502B (es) 2018-07-12
CN104271580B (zh) 2017-02-22
EP2844659A1 (en) 2015-03-11
KR20150006873A (ko) 2015-01-19
PT2844659T (pt) 2016-08-31
EA201401212A1 (ru) 2015-08-31
IL235414A (en) 2017-11-30
SG11201406997WA (en) 2014-11-27
HUE028325T2 (en) 2016-12-28
US20150133453A1 (en) 2015-05-14
ZA201408876B (en) 2017-06-28
US9174995B2 (en) 2015-11-03
ES2587939T3 (es) 2016-10-27
WO2013164061A1 (en) 2013-11-07
CA2872334A1 (en) 2013-11-07
SI2844659T1 (sl) 2016-10-28
CN104271580A (zh) 2015-01-07
EA027628B1 (ru) 2017-08-31
EP2844659B1 (en) 2016-05-25
AU2013257018B2 (en) 2017-02-16
RS55062B1 (sr) 2016-12-30
PL2844659T3 (pl) 2016-11-30
HRP20161033T1 (hr) 2016-10-21
AR090896A1 (es) 2014-12-17
WO2013164061A8 (en) 2014-11-06
CA2872334C (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX362939B (es) Derivados de (aza-)isoquinolinona.
MX362855B (es) Derivados de quinazolinona como inhidores poli (adp-ribosa) polimerasa (parp).
IN2014KN02601A (es)
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
MY177344A (en) Compounds and their methods of use
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2016014436A (es) Derivados de heterociclil-butanamida.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX367425B (es) Derivados de 4-carboxamido-isoindolinona como inhibidores selectivos de parp-1.
MX2014008864A (es) Derivados de triazolo[4,5-d]pirimidina.
MX2016001134A (es) Derivados 1,3-disustituidos de ciclopentano.
MX366140B (es) Derivados de urea de piperidinas.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX364859B (es) Derivados de imidazopirazinona.
MX2014006015A (es) Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
MX2018005515A (es) Derivados de 1,4-dicarbonil-piperidilo.
MX2015016760A (es) Derivados de ftalazina.
MX2016001934A (es) Derivados de ciclopentilamina 3-sustituidos.

Legal Events

Date Code Title Description
FG Grant or registration